230 related articles for article (PubMed ID: 8324743)
1. Penetration of mitomycin C in human bladder.
Wientjes MG; Badalament RA; Wang RC; Hassan F; Au JL
Cancer Res; 1993 Jul; 53(14):3314-20. PubMed ID: 8324743
[TBL] [Abstract][Full Text] [Related]
2. Bladder wall penetration of intravesical mitomycin C in dogs.
Wientjes MG; Dalton JT; Badalament RA; Drago JR; Au JL
Cancer Res; 1991 Aug; 51(16):4347-54. PubMed ID: 1907883
[TBL] [Abstract][Full Text] [Related]
3. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine.
Gao X; Au JL; Badalament RA; Wientjes MG
Clin Cancer Res; 1998 Jan; 4(1):139-43. PubMed ID: 9516962
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL
Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640
[TBL] [Abstract][Full Text] [Related]
5. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies.
Di Stasi SM; Giannantoni A; Massoud R; Dolci S; Navarra P; Vespasiani G; Stephen RL
Cancer Res; 1999 Oct; 59(19):4912-8. PubMed ID: 10519404
[TBL] [Abstract][Full Text] [Related]
6. Penetration of intravesical doxorubicin in human bladders.
Wientjes MG; Badalament RA; Au JL
Cancer Chemother Pharmacol; 1996; 37(6):539-46. PubMed ID: 8612307
[TBL] [Abstract][Full Text] [Related]
7. Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine.
Song D; Wientjes MG; Gan Y; Au JL
Clin Cancer Res; 1997 Jun; 3(6):901-9. PubMed ID: 9815765
[TBL] [Abstract][Full Text] [Related]
8. Electromotive delivery of mitomycin C into human bladder wall.
Di Stasi SM; Vespasiani G; Giannantoni A; Massoud R; Dolci S; Micali F
Cancer Res; 1997 Mar; 57(5):875-80. PubMed ID: 9041189
[TBL] [Abstract][Full Text] [Related]
9. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
10. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
Mauroy B; Bonnal JL; Prevost B; Chive M; Lhotellier V; Sozanski JP; Vanseymortier L; Stefaniak X
Prog Urol; 1999 Feb; 9(1):69-80. PubMed ID: 10212955
[TBL] [Abstract][Full Text] [Related]
11. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
[TBL] [Abstract][Full Text] [Related]
12. Bladder tissue pharmacokinetics of intravesical taxol.
Song D; Wientjes MG; Au JL
Cancer Chemother Pharmacol; 1997; 40(4):285-92. PubMed ID: 9225946
[TBL] [Abstract][Full Text] [Related]
13. Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
Hu L; Wientjes MG; Li J; Au JL
AAPS J; 2010 Dec; 12(4):586-91. PubMed ID: 20625863
[TBL] [Abstract][Full Text] [Related]
14. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
15. Intrascleral concentration vs depth profile of mitomycin-C after episcleral application: impact of applied concentration and volume of mitomycin-C solution.
Vass C; Georgopoulos M; el Menyawi I; Radda S; Nimmerrichter P
Exp Eye Res; 2000 May; 70(5):571-5. PubMed ID: 10870515
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of mitomycin C in cultured human bladder tumors.
Schmittgen TD; Wientjes MG; Badalament RA; Au JL
Cancer Res; 1991 Aug; 51(15):3849-56. PubMed ID: 1906778
[TBL] [Abstract][Full Text] [Related]
17. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
18. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel.
Chen D; Song D; Wientjes MG; Au JL
Clin Cancer Res; 2003 Jan; 9(1):363-9. PubMed ID: 12538489
[TBL] [Abstract][Full Text] [Related]
19. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
20. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
